Repairing an FDA IDE Clinical Study: Restoring Compliance for an Investigational Medical Device Trial

1. The Situation

An investment firm acquired a medical device start-up in the middle of an Investigational Device Exemption (IDE) study for the FDA. The Contract Research Organization (CRO) that had been managing the study was lost during the transition, leaving the study without any clinical oversight. The sponsor decided to focus on other aspects of the new business until more resources became available.

Without clinical oversight, multiple issues and discrepancies arose in the study:

• No active communication with the FDA.
• No organized structure for study files.
• The Trial Master File (TMF) was not up to date.
• Although safety was being monitored, there was no Data Safety Monitoring Board (DSMB) reviewing and adjudicating Adverse Events (AEs) that had occurred since the acquisition.
• Radiographic image analyses had not been performed.
• Minimal communication with the study sites.

2. The Solution

Clinical management of the study was taken over in late 2016. Immediate actions included:

• Restoring active communication with the FDA.
• Hiring dedicated personnel to lead the clinical management of the trial.
• Rescanning all Case Report Forms (CRFs) for transmission to the data management CRO.

Gaps in the study were then fully assessed, and a detailed plan was developed to bring the study back on track and into full regulatory compliance.

2.1 Data Management

Collaboration with the data management CRO ensured all data were cleaned and queried. The CRO created a new validated database and reentered all data collected via CRFs. Queries were issued for all missing or questionable data on the CRFs to resolve any potential data quality issues. A streamlined query resolution process was developed and implemented, routing queries through the data management team before delivery to the sites. This approach resulted in faster and cleaner resolutions.

2.2 Safety Management

A Data and Safety Monitoring Board (DSMB) was reestablished in the summer of 2017. The DSMB reviewed and adjudicated all Adverse Events (AEs) and Serious Adverse Events (SAEs) that had occurred in the study since the acquisition.

2.3 FDA Correspondence

An Annual Report was submitted to the FDA to reestablish formal contact. A complete Annual Report was then submitted in 2018, providing a full update on study status. The FDA accepted the 2018 Annual Report without further issues.

2.4 Trial Master File

The TMF Reference Model was adopted. All required documents were systematically identified, collected, and organized. Note-to-files were drafted where necessary to explain any gaps or resolutions. The sponsor now maintains a fully functioning TMF system, including both required paper copies and a complete electronic version.

2.5 Radiographic Imaging

A new contract was established with the radiographic core laboratory. In 2017, a detailed schedule was developed for the core laboratory to complete all radiographic analyses. These analyses were included in the Annual Report submitted to the FDA. Ongoing work with the core laboratory continues to ensure all radiographic analyses for the study are completed and delivered on time.

2.6 Site Monitoring and Satisfaction

Monitors based in the EU were utilized, and the sponsor’s field monitor was trained and managed to serve as clinical site monitors. Site monitors actively listened to site concerns and worked to bring sites back into compliance. As a result of completing the protocol in 2018, both European sites and several U.S. sites were closed, with the remaining U.S. clinical sites on track for timely closure. Previously dissatisfied sites were refocused, and all sites now receive regular monitoring.

3. Execution Phases and Outcomes

In less than two years, the study was fully restored to compliance with all regulatory requirements. The study is now on track for database lock and submission to the FDA for Premarket Approval (PMA) within the next year. The rapid and systematic repair demonstrates that even significantly compromised IDE studies can be successfully rescued through focused clinical management, robust data and safety processes, and proactive regulatory engagement.

4. Key Success Factors

• Immediate restoration of FDA communication and submission of Annual Reports.
• Comprehensive data cleaning and streamlined query resolution processes.
• Reestablishment of an independent DSMB for safety oversight.
• Systematic rebuilding of the TMF using the industry reference model.
• Timely resumption and completion of radiographic core laboratory analyses.
• Strengthened site monitoring with dedicated personnel and EU-based support.
• Efficient closure of completed sites while maintaining compliance at active sites.

This case illustrates the critical importance of proactive clinical oversight, detailed gap analysis, and coordinated execution when rescuing an ongoing FDA-regulated investigational device trial.